Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia
- 22 February 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (7), e307-e310
- https://doi.org/10.3324/haematol.2017.186908
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinibHaematologica, 2017
- The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophagesOncotarget, 2017
- How I manage ibrutinib-refractory chronic lymphocytic leukemiaPublished by American Society of Hematology ,2017
- Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialThe Lancet Oncology, 2016
- Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceTherapeutic Advances in Hematology, 2016
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II StudyClinical Cancer Research, 2016
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) FunctionJournal of Biological Chemistry, 2016
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaNew England Journal of Medicine, 2015
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003